Trump's Most-Favored-Nation Drug Pricing: What It Means for Your GLP-1 Costs

Here's a fact that used to make me furious during my years in insurance billing: the exact same syringe of Ozempic — same drug, same manufacturer, same factory — costs an American patient without insurance roughly $900 per month. A patient in Germany pays closer to $60. In the UK, the National Health Service pays even less. Same drug. Wildly different prices. That gap is what the Most-Favored-Nation executive order is designed to close.

Let me break down what MFN pricing actually means, how it got codified into TrumpRx.gov, and what it means for your specific GLP-1 costs in 2026.

What Is Most-Favored-Nation Drug Pricing?

"Most-Favored-Nation" is a trade policy term that, in this drug pricing context, means the United States will not pay more for a prescription drug than the lowest price paid by any comparable developed nation. It's a form of international reference pricing — a tool that countries like Germany, France, Canada, and Australia have used for decades to control drug costs through government purchasing power.

The logic is simple: pharmaceutical manufacturers sell the same drugs at dramatically different prices in different countries because they can. National health systems in Europe and Canada negotiate drug prices using the government's purchasing leverage and, in some cases, explicit price controls. American patients — particularly the uninsured — have historically had no such leverage. The MFN executive order changes that by anchoring U.S. federal purchasing to international benchmarks.

How the MFN Order Became TrumpRx.gov

The Most-Favored-Nation executive order — signed and directed at federal drug purchasing — was implemented through TrumpRx.gov, the direct-purchasing portal launched February 5, 2026. The portal gives individual patients and providers access to federally negotiated MFN prices, bypassing the traditional pharmacy benefit manager infrastructure that has historically kept prices opaque and high.

What made the May 18, 2026 expansion significant is scale. By that date, 17 major pharmaceutical manufacturers — covering 86% of the branded drug market by revenue — had signed agreements to provide MFN-compliant pricing through the portal. That's not a pilot program. That's a fundamental restructuring of the U.S. drug pricing model for a substantial portion of the prescription market.

Which GLP-1 Drugs Are Affected?

All four major branded GLP-1 receptor agonists in the U.S. market are covered under the MFN framework as of May 2026:

• Ozempic (semaglutide, Novo Nordisk) — primarily prescribed for type 2 diabetes
• Wegovy (semaglutide, Novo Nordisk) — FDA-approved for chronic weight management
• Mounjaro (tirzepatide, Eli Lilly) — dual GIP/GLP-1 agonist, for type 2 diabetes
• Zepbound (tirzepatide, Eli Lilly) — FDA-approved for chronic weight management

Both Novo Nordisk and Eli Lilly signed MFN agreements as part of the May 2026 expansion. These are the same manufacturers that have long cited research and development costs to justify U.S. pricing — and the same manufacturers that have been selling these drugs at a fraction of U.S. prices in European markets for years.

The Projected Cost Decreases — With Real Numbers

Here's what MFN pricing has delivered for GLP-1 patients as of May 2026:

To put the Wegovy number in perspective: a patient who has been paying retail for 12 months ($16,200) versus TrumpRx MFN pricing for the same period ($4,188) has paid $12,012 more than necessary. That's a used car. That's a year of college tuition at many community colleges. That's the difference between continuing therapy and abandoning it because the math doesn't work.

I've been through this myself — three months fighting an insurance appeal for Wegovy coverage before I finally got it approved. I know what it means to do the math on whether you can keep taking the medication that's working. These numbers matter.

What Countries' Prices Are Being Referenced?

The MFN benchmarking uses price data from a basket of comparable developed nations. The reference countries include:

• United Kingdom — NHS negotiated prices, set through the Pharmaceutical Price Regulation Scheme (PPRS)
• Germany — AMNOG early benefit assessment pricing
• France — government-regulated reimbursed prices
• Canada — Patented Medicine Prices Review Board (PMPRB) guidelines
• Japan — National Health Insurance drug price listing

The MFN price is derived from the lowest price among comparable countries — not an average. This is a meaningful distinction. It means the U.S. federal benchmark isn't meeting these countries in the middle; it's anchoring to their most aggressive price point.

Timeline: How Did We Get Here?

• February 5, 2026: TrumpRx.gov launches with initial drug portfolio
• March-April 2026: Manufacturer negotiations accelerate; major pharma companies begin signing MFN agreements
• May 18, 2026: Major expansion announced — 17 manufacturers, 86% of branded drug market, GLP-1 drugs explicitly confirmed under coverage
• Ongoing: Additional manufacturers and drug categories expected to be added through 2026

What Patients Should Do Right Now

The policy is live. The prices are live. Here's the concrete action sequence I'd recommend for any GLP-1 patient currently paying out-of-pocket or with insufficient coverage:

1. Check TrumpRx.gov eligibility now. The eligibility determination takes minutes. Don't assume you don't qualify — check.
2. Run your numbers through our calculator. Our GLP-1 cost calculator lets you compare TrumpRx MFN pricing against your current cost, GoodRx, and other available programs in one place.
3. Bring your TrumpRx authorization to your pharmacy. Major pharmacy chains are participating. If yours isn't, the portal will show you ones nearby that are.
4. Ask your doctor to confirm your prescription is for the correct drug name and dose that matches the MFN-covered formulation. Dosing tiers matter for which MFN price applies.

What MFN Pricing Doesn't Fix (Yet)

Here's what they don't tell you: MFN pricing through TrumpRx is a major step, but it doesn't resolve every GLP-1 affordability problem. Patients with Medicare who are already covered under Part D may not benefit directly from TrumpRx, since Medicare has its own negotiation track under the Inflation Reduction Act. Manufacturer savings cards — which can bring costs to $0 for commercially insured patients — remain the best option for that group.

And for patients who want brand-name GLP-1 drugs but whose state regulations or insurance situation creates barriers TrumpRx doesn't address, telehealth compounded programs remain a parallel option — different regulatory pathway, but often price-competitive.

The MFN executive order is the most consequential drug pricing change for GLP-1 patients in years. But no single policy fixes every situation. Run your numbers, know your options, and make the decision that actually works for your circumstances.